Objective: Much controversy relates to the risk of non-synchronous second primary malignancies (NSSPM) after radioactive iodine treatment (RAI-131) in differentiated thyroid cancer (DTC) patients. This study evaluated the relationship between RAI-131 and NSSPM in DTC survivors with long-term follow-up. Materials and methods: Retrospective analysis of 413 DTC cases was performed; 252 received RAI-131 and 161 were treated with thyroidectomy alone. Exclusion criteria were: prior or synchronous non-thyroidal malignancies (within the first year), familial syndromes associated to multiple neoplasms, ionizing radiation exposure or second tumors with unknown histopathology. Results: During a mean follow-up of 11.0 ± 7.5 years, 17 (4.1%) patients developed solid NSSPM. Patients with NSSPM were older than those without (p = 0.02). RAI-131 and I-131 cumulative activity were similar in patients with and without NSSPM (p = 0.18 and p = 0.78, respectively). Incidence of NSSPM was 5.2% in patients with RAI-131 treatment and 2.5% in those without RAI-131 (p = 0.18). Using multivariate analysis, RAI-131 was not significantly associated with NSSPM occurrence (p = 0.35); age was the only independent predictor (p = 0.04). Under log rank statistical analysis, after 10 years of follow-up, it was observed a tendency of lower NSSPM-free survival among patients that received p = 0.06), what was not affected by age at DTC diagnosis. Conclusion: In our cohort of DTC survivors, with a long-term follow-up period, RAI-131 treatment and I-131 cumulative dose were not significantly associated with NSSPM occurrence. A tendency of premature NSSPM occurrence among patients treated with RAI-131 was observed, suggesting an anticipating oncogenic effect by interaction with other risk factors.
INTRODUCTION

D
ifferentiated thyroid carcinoma (DTC), including papillary, follicular and its variants, accounts for over 90% of all the malignant neoplasms of the thyroid gland (1) . DTC incidence has been rising substantially all over the world. The exact reasons for the rising incidence are unclear, but it might be related to better detection by ultrasonography and thyroid fine needle aspiration; improved recognition of histological subtypes; and possible increased exposure to unknown risk factors (2) (3) (4) . The Brazilian National Cancer Institute (INCa) estimates 9200 new cases of DTC in Brazil in 2014, with an expected incidence (per 100,000 habitants) of 1.15 and 7.89, among men and women, respectively (5) .
Treatment of DTC involves surgery with elective radioactive iodine-131 treatment (RAI-131) in an individualized approach (6) (7) (8) (9) . Overall prognosis of DTC after treatment is favorable with a low mortality rate (1) . Therefore, the great majority of patients with DTC will have a long-term survival and follow-up period. Concerns related to the long-term negative effects of RAI-131 are increasing and a more selective use of RAI-131 is being advocated (10) . Researchers have noticed non rare cases of non-synchronous second primary malignancies (NSSPM) along the follow-up of non-familial DTC, exceptions made to the known syndromes in which DTC is associated with other malignant neoplasms (11) . Some authors advocated the relationship between RAI-131 and oncogenic effects (12) (13) (14) (15) (16) , as suggested by recent studies with DTC patients treated with RAI-131 (15, 16) . Nevertheless, an Iranian cohort demonstrated that the increased risk of second malignant neoplasms occurred only when the cumulative dose of I-131 exceeded 4.0 GBq (1.08Ci) (17) . Furthermore, other studies reported no influence of RAI-131 for DTC on the incidence of NSSPM (18) .
Therefore, there is still much controversy relating the risk of NSSPM with RAI-131. The aims of this study were to evaluate the relationship between the RAI-131 treatment for DTC and the incidence of NSSPM in a cohort of DTC survivors with long-term follow-up, and to evaluate other possible factors associated with NSSPM in DTC survivors.
MATERIALS AND METHODS
Study population
From 562 patients with histopathological diagnosis of thyroid cancer treated at the Federal University of Rio de Janeiro between January 1 st of 1979 and December 31 of 2009, 413 met the inclusion and exclusion criteria. The present study was performed under the research protocol 178/06 approved by local Research Ethics Committee.
Inclusion criteria were DTC confirmed by histopathology and a minimal follow-up of 3 years after surgery. Two hundred and fifty two patients received at least one RAI-131 therapeutic dose, and 161 were submitted to thyroidectomy alone.
Exclusion criteria were: second malignancy prior to or in the first year of the diagnosis of the DTC (classified as synchronous); history of previous exposure to ionizing radiation; familial syndromes known to be related to cancer of other sites; and/or the presence of tumors with unknown histopathological nature which could represent either DTC metastasis or second primary malignancy.
RAI-131 treatment
Total thyroidectomy was performed in all patients with DTC diagnoses. RAI-131 treatment after surgery respected the international recommendations, and was indicated for patients with tumors larger than 1 centimeter (cm), multicentricity, capsular or angiolymphatic invasion, extra-thyroidal extension, lymphonodal or distant metastasis and in case of any evidence of postoperative remnant disease on the neck. RAI-131 was adminis tered after levothyroxine withdrawal for 30 days, or, in selected cases, after recombinant TSH administration. Eight days after treatment, patients were submitted to a post-dose whole body scan (WBS), and a therapeutic control WBS was performed 6-12 months after each dose. The standard radioactivity indicated was 100mCi (3.7GBq); major doses were administered in the presence of lymphonodal or distant metastasis. Subsequent doses were administered in individualized manner, when there was evidence of residual radioactive avid disease.
Follow-up
All patients were assigned to a regular and periodic follow-up plan for thyroid cancer, which included measurement of serum thyroglobulin and cervical ultrasonography at 6-12 months intervals. Further complementary tests, such as computed tomography and I-131 whole body scan, were performed as an individualized approach whenever clinically indicated. There was no active screening for other malignancies. Only documented non-thyroid neoplasms were considered as NSSPM. NSSPM was diagnosed in the presence of suggestive signs and symptoms followed by complimentary investigation.
Data collection
For this retrospective analysis, we recorded in a datasheet information of each case including gender, date of diagnosis, age at diagnosis, histophatological subtypes of DTC, the first dose and the subsequent cumulative I-131 dose for the group treated with RAI-131, followup period, data about the NSSPM (age at diagnosis, subtype) and cause of death (when applicable).
Outcomes
Primary outcomes of the study were to determine the incidence of NSSPM and to evaluate the association of NSSPM with RAI-131. Secondary outcomes were to evaluate other possible factors associated with NSSPM in patients with DTC.
The endpoint of the study was determined for each patient as the date of diagnosis of NSSPM, death, loss of follow-up or the closing date of data collection (December 31, 2012), whichever occurred first.
Radioactive iodine and second primary malignancy
Arch Endocrinol Metab.
A first analysis was performed with the entire population in order to evaluate the incidence of NSSPM. Patients where then distributed into two groups for analysis: with and without NSSPM. We aimed to evaluate clinical factors associated with NSSPM in DTC patients.
In order to evaluate the incidence of NSSPM in patients treated with RAI-131 a separate analysis was performed which distributed patients in two groups: with and without RAI-131 treatment.
At last, patients who developed NSSPM were separately analyzed. Clinical characteristics and the exposure impact of RAI-131 in these patients were evaluated.
Statistical analysis
Statistical analysis was processed using SPSS for Windows 13.0 (SPSS Inc. 2004). Under univariate analysis to compare between groups, categorical variables were evaluated by Fisher or chi-square tests, and ordinal variables were evaluated by Mann-Whitney. Multivariate analysis was performed by logistic regression analysis (enter method). Endpoint-free cumulative probability was defined, for each group, using Kaplan-Meier method, and comparison between curves was obtained by log-rank (Mantel-Cox) statistics. Significance criteria were defined in 5% (p < 0.05).
RESULTS
Baseline characteristics of the entire population (n = 413) described in table 1 were: mean age of 44.1 ± 15.3 years, 362 (87.6%) women, 309 (74.8%) papillary carcinoma subtype, and 252 (61%) patients were submitted to RAI-131. Mean follow-up period since diagnosis was 11.0 ± 7.5 years. In the end of the follow-up, 6 (1.4%) patients died, 2 of them due to thyroid cancer (specific mortality rate 0.48%). During the follow-up period, 17 (4.1%) patients developed NSSPM.
Clinical characteristics of patients with and without NSSPM are demonstrated in table 2. It was observed significant difference of age on DTC diagnosis. Gender, histological type, RAI-131 treatment and I-131 cumulative activity were similar in both groups.
Multivariate analysis by logistic regression was performed to evaluate simultaneous influence of independent variables on the occurrence of NSSPM (Table 3) . Age at diagnosis was the only significant predicting factor independently associated to NSSPM occurrence (p = 0.04). RAI-131 was not significantly associated with NSSPM occurrence (p = 0.35). The incidence of NSSPM in patients with and without RAI-131 treatment is demonstrated in figure 1 . There was no statistically difference between the groups, since the incidence of NSSPM in patients that received RAI-131 was of 5.2% and in those that did not receive RAI-131 was of 2.5% (p = 0.18). The individual characteristics of the 17 patients who developed NSSPM are described in table 4. In order to evaluate the RAI-131 exposure impact on NSSPM occurrence of these patients, the endpoint-free survival cumulative probability was calculated by Kaplan-Meier method for patients with NSSPM treated with and without RAI-131 and, consecutively, endpoint-free survival probability curves were compared by log rank statistical analysis. Patients with NSSPM treated with RAI-131 had an endpoint-free survival probability ratio of 0.96 or 96% and those treated without RAI-131 of 0.87 or 87% (p = 0.06) (Figure 2A) . Thus, assuming the increased risk exposure time for the RAI-131 treated patients as the time course since the first dose until the endpoint (NSS-PM occurrence), after 10 years of follow-up it was observed a tendency of lower endpoint-free survival among RAI-131 treated subjects (Figure 2A ). Considering the difference of age at DTC diagnosis between groups, we proposed to evaluate Kaplan-Meier endpoint-free curves stratified by age range (45 years cut-off) and it was not observed significant difference on age-adjusted log rank statistical analysis (p = 0.18) ( Figure 2B ).
DISCUSSION
DTC incidence is increasing worldwide and given its overall good prognosis, an uprising number of DTC survivors will be followed for a long-time period. Concerns relating to the occurrence of NSSPM in DTC survivors and its relation to RAI-131 are increasing. In our study, we evaluated DTC survivors for a long-time period, aiming the occurrence of NSSPM and its relationship with RAI-131 treatment. In our cohort of DTC survivors, an incidence of 4.1% of NSSPM was observed and RAI-131 treatment was not significantly associated with NSSPM, although a tendency to a lower NSSPMfree survival was observed, suggesting an anticipating role of RAI-131 exposure on the NSSPM occurrence. A greater risk of second primary malignancies among DTC survivors in comparison to general population has been shown by previous studies (19, 20) . The incidence of 4.1% cases of NSSPM in our cohort is in accordance to the previous literature description of 1.2%-8.9% (17, 18, 21, 22 ). It has been described an increased risk among DTC survivors for secondary malignancies of salivary glands, stomach, breast, central nervous system, colorectal, prostate, genitourinary tract, kidney, adrenal gland, bone and joints, soft tissue sarcoma and hematological cancers (23) . In this study, we found only solid NSSPM and the most frequent site was breast; followed by skin and prostate; uterus, gastrointestinal and lung cancer were also described. The association between breast cancer and DTC has been described by previous studies both as non-synchronous and synchronous tumors, as well as the association with auto-immune thyroid disorders (21, 22, 24) .
Many factors may account for the elevated risk of secondary malignancies in DTC survivors. Environmental and genetic mechanisms may play an important role, since many tumors exhibit similar genetic profiles to DTC. Furthermore, much controversy exists about whether RAI-131 affects this endpoint. Data on RAI-131 influence on secondary malignancies are confounding and it depends on the type of secondary tumor analyzed (15, 21, 22) .
In the present work, during a long-term follow--up of 11.0 ± 7.5 years, no significant association was found between RAI-131 and the overall occurrence of solid NSSPM in DTC survivors. Similarly, previous studies, despite the lower follow-up period, also have described that the overall rate of NSSPM was not increased by RAI-131, although the hazard of event may be increased in patients that received higher activities (17, 18, 20) . This dose-dependent effect was not observed in our study, what could be due to the relative small number of patients who developed NSSPM. Furthermore, the overall cumulative I-131 activity of the patients included in this study was low and evidence in the literature indicates that the chance of NSSPM is increased in patients who had received a cumulative activity of I-131 exceeding 40 GBq (1.08 Ci) (17) .
A meta-analysis by Sawka and cols. demonstrated a slight increase in the polled estimate risk for NSS-PM in DTC survivors that received RAI-131, with a 1% greater absolute risk in the RAI-131 treated than in non-treated DTC survivors. Notably, it demonstrated a specific increased risk of leukemia incidence, but no significant increased risks of other solid malignancies (15) . Similar findings were reported by Brown and cols., with data from the largest cohort of DTC survivors, describing an increased overall risk of NSSPM among DTC survivors, and an increased specific risk of leukemia and stomach cancer in RAI-131 treated patients (22) . Instead, Rubino and cols. described a linear dose-response relationship among RAI-131 and the occurrence of leukemia and only some specific solid malignancies (colorectal, salivary glands, bone, soft tissue cancer), with no association with others solid malignancies (breast, kidney, central nervous system) (21) . In our cohort of DTC survivors, we detected only solid tumors and no cases of leukemia were diagnosed during the follow-up, what might explain the lack of association between RAI-131 and NSSPM. Furthermore, the main NSSPM found was breast cancer, which has been associated with DTC and previous studies have corroborated no influence of RAI-131 on its development (21, 22) .
An interesting finding of our study was a statistical tendency of RAI-131 impact on anticipating NSSPM occurrence in DTC survivors, considering the endpoint-free cumulative probability calculated by Kaplan--Meier method, and this effect was more noticeable after 10 years. This may suggest that RAI-131, despite not directly associated with the development of NSS-PM, may interact with other genetic and environmental factors leading to premature occurrence of NSSPM. Still, given that our mean follow-up period was of 11.0 ± 7.5 years and the small number of patients with NSS-PM that did not receive RAI-131 treatment, further studies with longer follow-up period and a larger cohort of patients will be needed to confirm this finding. Furthermore, we cannot rule out a surveillance bias, in which patients with DTC and RAI-131 were submitted to closer follow-up and diagnosed second tumors earlier.
This study also evaluated variables other than RAI-131 that could be associated with NSSPM, such as age, gender and DTC histological subtype. Age at DTC diagnosis was the only independent factor with significantly associated with NSSPM, corroborating findings of previous studies (16, 25) . Older age was observed in patients with DTC that developed NSSPM.
It is also important to address that, given our study criteria, 15 patients were excluded because of other primary malignant neoplasms prior or synchronous to DTC. This can be comparable to the results of one Dutch and one Turkish studies in which approximately half of the patients had thyroid cancer not in the first place, but after another malignant neoplasm, what suggests common mechanisms other than causal relation (20, 26) . In the same way, it was noticed similar frequency of second malignancy both before and after RAI-131 in a subset of Brazilian DTC patients studied by Hirosawa and cols. (18) .
Our study strengths rely on a long-term follow-up of a cohort with significant numbers of DTC survivors that included patients with and without RAI-131, carefully surveyed. Nevertheless, the study has limitations inherent to its retrospective design, which includes the inability to infer a cause-effect relationship and the probability of selection bias. Furthermore, no active investigation for secondary malignances was performed and only clinically apparent disease was diagnosed; thus the possibility of silent NSSPM not diagnosed must be considered.
CONCLUSIONS
In our cohort of DTC survivors, followed by a longterm period, an incidence of 4.1% NSSPM was observed, related to the occurrence of solid malignancies. We did not found a statically significant association between RAI-131 treatment or cumulative I-131 activity and NSSPM occurrence. Patients with more advanced age at DTC diagnoses were under greater risk of NSSPM development. This study provides further support that the role of RAI-131 on NSSPM occurrence might be related to the type of secondary malignancy, with no evidence of increased risk of solid malignancies related to RAI-131 in our cohort of DTC survivors followed by a long time period.
Interestingly, our study suggests a statistical tendency of premature NSSPM occurrence among patients treated with RAI-131, despite the small number of DTC patients with NSSPM. This finding indicates that RAI-131 may play a role on anticipating NSSPM occurrence by interacting with many other risk factors involved in the oncogenesis, such as genetics and environmental factors. Further studies to evaluate this issue will be necessary.
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